




RealRate

PHARMACEUTICAL 2022

CymaBay Therapeutics Inc.
Rank 280 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

CymaBay Therapeutics Inc. Rank 280 of 475

The relative strengths and weaknesses of CymaBay Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CymaBay Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 102% points. The greatest weakness of CymaBay Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is -161%, being 115% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	191,099
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,366
Liabilities, Non-Current	695
Other Assets	10,041
Other Compr. Net Income	-21
Other Expenses	0
Other Liabilities	50,320
Other Net Income	-2,416
Property and Equipment	1,178
Research and Development	64,542
Revenues	0
Selling, General and Administrative Expense	23,040

Output Variable	Value in 1000 USD
Assets	202,318
Liabilities	69,381
Expenses	87,582
Stockholders Equity	132,937
Net Income	-89,998
Comprehensive Net Income	-90,008
Economic Capital Ratio	-161%

